Excited to share our latest paper that is now available online in Blood! @BloodPortfolio XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53-Mutated Myeloid Malignancies @md_padron@MoffittNews
https://t.co/DGEkdi1kLm
Super excited to see our collaboration with @md_padron online in Blood @BloodPortfolio! Congrats to first author Traci Kruer @fairoza21! 🔥XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53-Mutated Myeloid Malignancies https://t.co/TQUQzmLpyc
Tomorrow at #ASH22: Dr. Traci Kruer (@fairoza21) of @MoffittNews presents on overexpression as a mechanism of resistance that can be therapeutically exploited for treatment. @ASH_hematology Read more ➡️ https://t.co/e4P2FwULkb
#MoffittGR Would like to thank @HillsboroughSch for recognizing Moffitt Cancer’s Dr. Traci Krurer to encourage young people to pursue careers in medicine and research.